Cystic fibrosis transmembrane conductance regulator dysfunction in VIP knockout mice

American Journal of Physiology - Cell Physiology

Volumn 307, Issue 2, 2014, Pages

  Alcolado, Nicole G ^a   Conrad, Dustin J ^a   Poroca, Diogo ^a   Li, Mansong ^a   Alshafie, Walaa ^a   Chappe, Frederic G ^a   Pelis, Ryan M ^b   Anini, Younes ^a   Xu, Zhaolin ^c   Hamidi, Sayyed ^d   Said, Sami I ^d   Chappe, Valerie M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

CFTR; Cystic fibrosis; Epithelium; VIP; VIP knockout mice

Indexed keywords

CFTR; CYSTIC FIBROSIS; EPITHELIUM; VIP; VIP-KNOCKOUT MICE;

ANIMALS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; INTESTINE, SMALL; LUNG; MICE; MICE, KNOCKOUT; RESPIRATORY MUCOSA; TRACHEA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84904279683     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00293.2013     Document Type: Article

References (44)

1. Alcolado N, Conrad DJ, Rafferty S, Chappe FG, Chappe VM. VIPdependent increase in F508del-CFTR membrane localization is mediated by PKCb. Am J Physiol Cell Physiol 301: C53-C65, 2011.
2. Alessandrini F, Thakkar M, Foda HD, Said SI, Lodi R, Pakbaz H, Schraufnagel DE. Vasoactive intestinal peptide enhances lung preservation. Transplantation 56: 964-973, 1993.
3. Ameen NA, Ardito T, Kashgarian M, Marino CR. A unique subset of rat and human intestinal villus cells express the cystic fibrosis transmembrane conductance regulator. Gastroenterology 108: 1016-1023, 1995.
4. Ameen NA, Martensson B, Bourguinon L, Marino C, Isenberg J, McLaughlin GE. CFTR channel insertion to the apical surface in rat duodenal villus epithelial cells is upregulated by VIP in vivo. J Cell Sci 112: 887-894, 1999.
5. Ameen NA, van Donselaar E, Posthuma G, de Jonge H, McLaughlin G, Geuze HJ, Marino C, Peters PJ. Subcellular distribution of CFTR in rat intestine supports a physiologic role for CFTR regulation by vesicle traffic. Histochem Cell Biol 114: 219-228, 2000.
6. Bradbury NA, Jilling T, Berta G, Sorscher EJ, Bridges RJ, Kirk KL. Regulation of plasma membrane recycling by CFTR. Science 256: 530-532, 1992.
7. Brockman-Schneider RA, Amineva SP, Bulat MV, Gern JE. Serial culture of murine primary airway epithelial cells and ex vivo replication of human rhinoviruses. J Immunol Methods 339: 264-269, 2008.
8. Chappe FG, Loewen ME, Hanrahan JW, Chappe VM. VIP increases CFTR levels in the apical membrane of Calu-3 cells through a PKCdependent mechanism. J Pharmacol Exp Ther 327: 226-238, 2008.
9. Chappe V, Hinkson DA, Howell LD, Evagelidis A, Liao J, Chang XB, Riordan JR, Hanrahan JW. Stimulatory and inhibitory protein kinase C consensus sequences regulate the cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci USA 101: 390-395, 2004.
10. Chappe V, Hinkson DA, Zhu T, Chang XB, Riordan JR, Hanrahan JW. Phosphorylation of protein kinase C sites in NBD1 and the R domain control CFTR channel activation by PKA. J Physiol 548: 39-52, 2003.
11. Chaudry G, Navarro OM, Levine DS, Oudjhane K. Abdominal manifestations of cystic fibrosis in children. Pediatr Radiol 36: 233-240, 2006.
12. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, Smith AE. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63: 827-834, 1990.
13. Couvineau A, Laburthe M. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol 166: 42-50, 2012.
14. Dray-Charier N, Paul A, Veissiere D, Mergey M, Scoazec JY, Capeau J, Brahimi-Horn C, Housset C. Expression of cystic fibrosis transmembrane conductance regulator in human gallbladder epithelial cells. Lab Invest 73: 828-836, 1995.
15. Durie PR, Kent G, Phillips MJ, Ackerley CA. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol 164: 1481-1493, 2004.
16. Glozman R, Okiyoneda T, Mulvihill CM, Rini JM, Barriere H, Lukacs GL. N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic. J Cell Biol 184: 847-862, 2009.
17. Groneberg DA, Rabe KF, Fischer A. Novel concepts of neuropeptidebased drug therapy: vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol 533: 182-194, 2006.
18. Hamidi SA, Prabhakar S, Said SI. Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur Respir J 31: 135-139, 2008.
19. Hamidi SA, Szema AM, Lyubsky S, Dickman KG, Degene A, Mathew SM, Waschek JA, Said SI. Clues to VIP function from knockout mice. Ann NY Acad Sci 1070: 5-9, 2006.
20. Heinz-Erian P, Dey RD, Flux M, Said SI. Deficient vasoactive intestinal peptide innervation in the sweat glands of cystic fibrosis patients. Science 229: 1407-1408, 1985.
21. Jacquot J, Puchelle E, Hinnrasky J, Fuchey C, Bettinger C, Spilmont C, Bonnet N, Dieterle A, Dreyer D, Pavirani A. Localization of the cystic fibrosis transmembrane conductance regulator in airway secretory glands. Eur Respir J 6: 169-176, 1993.
22. Kalin N, Claass A, Sommer M, Puchelle E, Tummler B. DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis. J Clin Invest 103: 1379-1389, 1999.
23. Laburthe M, Couvineau A, Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 28: 1631-1639, 2007.
24. Langer I. Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies. Front Endocrinol (Lausanne) 3: 129, 2012.
25. Lehrich RW, Aller SG, Webster P, Marino CR, Forrest JN, Jr. Vasoactive intestinal peptide, forskolin, and genistein increase apical CFTR trafficking in the rectal gland of the spiny dogfish, Squalus acanthias. Acute regulation of CFTR trafficking in an intact epithelium. J Clin Invest 101: 737-745, 1998.
26. Lelievre V, Favrais G, Abad C, Adle-Biassette H, Lu Y, Germano PM, Cheung-Lau G, Pisegna JR, Gressens P, Lawson G, Waschek JA. Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease. Peptides 28: 1688-1699, 2007.
27. Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 32: 1289-1294, 2008.
28. Murthy KS, Grider JR. VIP. In: Handbook of Biologically Active Peptides (2nd ed.), edited by Kastin AJ. San Diego, CA: Elsevier, 2012, chapt. 184, p. 1354-1360.
29. Prasse A, Zissel G, Lutzen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, Rensing-Ehl A, Bacher G, Cavalli V, Bevec D, Delgado M, Muller-Quernheim J. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 182: 540-548, 2010.
30. Rafferty S, Alcolado N, Norez C, Chappe F, Pelzer S, Becq F, Chappe V. Rescue of functional F508del-CFTR by VIP in the human nasal epithelial cell line JME/CF15. J Pharmacol Exp Ther 331: 2-13, 2009.
31. Said SI. Animal models of airway hyperresponsiveness. Eur Respir J 33: 217-218, 2009.
32. Said SI. The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann NY Acad Sci 1144: 148-153, 2008.
33. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang YP, Chen JJ, Waschek JA, Kort S. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115: 1260-1268, 2007.
34. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 169: 1217-1218, 1970.
35. Said SI, Mutt V, Yoshida T, Hara N. Vasoactive polypeptides from normal lung. Chest 67, Suppl 2: 44S, 1975.
36. Sami SI, Chappe V, Sayyed HA. VIP. In: Handbook of Biologically Active Peptides (2nd ed.), edited by Kastin AJ. New York: Elsevier, 2012, chapt. 209, p. 1535-1548.
37. Savage MV, Brengelmann GL, Buchan AM, Freund PR. Cystic fibrosis, vasoactive intestinal polypeptide, and active cutaneous vasodilation. J Appl Physiol 69: 2149-2154, 1990.
38. Sharma RK, Addis BJ, Jeffery PK. The distribution and density of airway vasoactive intestinal polypeptide (VIP) binding sites in cystic fibrosis and asthma. Pulm Pharmacol 8: 91-96, 1995.
39. Szema AM, Hamidi SA, Koller A, Martin DW. Vasoactive intestinal peptide knockout (VIP KO) mouse model of sulfite-sensitive asthma: upregulation of novel lung carbonyl reductase. BMC Immunol 12: 66-2172-12-66, 2011.
40. Szema AM, Hamidi SA, Lyubsky S, Dickman KG, Mathew S, Abdel-Razek T, Chen JJ, Waschek JA, Said SI. Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 291: L880-L886, 2006.
41. Szema AM, Hamidi SA, Smith SD, Benveniste H. VIP gene deletion in mice causes cardiomyopathy associated with upregulation of heart failure genes. PLos One 8: e61449, 2013.
42. Wattchow DA, Furness JB, Gibbins IL, Little, KE, Carter RF. Vasoactive intestinal peptide immunoreactive fibres are deficient in intestinal and nasal mucosa affected by cystic fibrosis. J Gastroenterol Hepatol 3: 549-555, 1988.
43. Webster P, Vanacore L, Nairn AC, Marino CR. Subcellular localization of CFTR to endosomes in a ductal epithelium. Am J Physiol Cell Physiol 267: C340-C348, 1994.
44. Wilke M, Buijs-Offerman RM, Aarbiou J, Colledge WH, Sheppard DN, Touqui L, Bot A, Jorna H, de Jonge HR, Scholte BJ. Mouse models of cystic fibrosis: phenotypic analysis and research applications. J Cyst Fibros 10, Suppl 2: S152-S171, 2011.